Neale, HollyMichelon, MelissaJacob, SusanPinkston, MaryUkaegbu, RebeccaZamor, WaldoMorrison, EmilyDeng, AprilLevin, Nikki A.2022-08-232022-08-232021-08-312022-03-02<p>Neale H, Michelon M, Jacob S, Pinkston M, Ukaegbu R, Zamor W, Morrison E, Deng A, Levin NA. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis. J Am Acad Dermatol. 2021 Aug 31:S0190-9622(21)02390-2. doi: 10.1016/j.jaad.2021.08.045. Epub ahead of print. PMID: 34478783.</p>1097-678710.1016/j.jaad.2021.08.04534478783https://hdl.handle.net/20.500.14038/49098The topical chemotherapeutic agent 5-fluorouracil (5-FU) is commonly used to treat squamous cell carcinoma in situ (SCCIS) and superficial basal cell carcinoma (sBCC). Additional investigation is needed to understand whether topical 5-FU, under real-world conditions, has comparable treatment success to procedures for epidermally-limited keratinocyte carcinomas. Approval was obtained from the University of Massachusetts Medical School institutional review board to perform a retrospective chart review.en-UScarcinomas5-fluorouracilDermatologySkin and Connective Tissue DiseasesJournal Articlehttps://escholarship.umassmed.edu/som_pubs/1428302329som_pubs/14